SG10201401690XA - Antibody purification by cation exchange chromatography - Google Patents

Antibody purification by cation exchange chromatography

Info

Publication number
SG10201401690XA
SG10201401690XA SG10201401690XA SG10201401690XA SG10201401690XA SG 10201401690X A SG10201401690X A SG 10201401690XA SG 10201401690X A SG10201401690X A SG 10201401690XA SG 10201401690X A SG10201401690X A SG 10201401690XA SG 10201401690X A SG10201401690X A SG 10201401690XA
Authority
SG
Singapore
Prior art keywords
cation exchange
exchange chromatography
antibody purification
antibody
purification
Prior art date
Application number
SG10201401690XA
Inventor
Benedicte Andree Lebreton
Deborah Ann O'connor
Aurelia Safta
Mandakini Sharma
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201401690X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201401690XA publication Critical patent/SG10201401690XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
SG10201401690XA 2007-10-30 2008-10-29 Antibody purification by cation exchange chromatography SG10201401690XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98382507P 2007-10-30 2007-10-30

Publications (1)

Publication Number Publication Date
SG10201401690XA true SG10201401690XA (en) 2014-06-27

Family

ID=40262967

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011073087A SG175597A1 (en) 2007-10-30 2008-10-29 Antibody purification by cation exchange chromatography
SG10201401690XA SG10201401690XA (en) 2007-10-30 2008-10-29 Antibody purification by cation exchange chromatography

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011073087A SG175597A1 (en) 2007-10-30 2008-10-29 Antibody purification by cation exchange chromatography

Country Status (32)

Country Link
US (3) US20090148435A1 (en)
EP (4) EP2215117B2 (en)
JP (5) JP5237382B2 (en)
KR (3) KR20150008503A (en)
CN (3) CN101889025B (en)
AR (2) AR069097A1 (en)
AU (1) AU2008318865B2 (en)
BR (1) BRPI0817182A2 (en)
CA (1) CA2703279C (en)
CL (1) CL2008003218A1 (en)
CO (1) CO6280422A2 (en)
CY (1) CY1116129T1 (en)
DK (3) DK2215117T4 (en)
ES (3) ES2572958T3 (en)
HK (4) HK1143821A1 (en)
HR (2) HRP20150282T4 (en)
HU (3) HUE037409T2 (en)
IL (4) IL205310A0 (en)
ME (1) ME02101B (en)
MX (1) MX2010004740A (en)
NZ (1) NZ584839A (en)
PE (1) PE20091434A1 (en)
PH (1) PH12013501128A1 (en)
PL (3) PL2565206T3 (en)
PT (1) PT2215117E (en)
RS (1) RS53850B2 (en)
RU (1) RU2498991C2 (en)
SG (2) SG175597A1 (en)
SI (3) SI2215117T2 (en)
TW (2) TWI554517B (en)
WO (1) WO2009058812A1 (en)
ZA (2) ZA201002850B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
KR20190110637A (en) * 2005-01-21 2019-09-30 제넨테크, 인크. Fixed dosing of her antibodies
RU2404806C2 (en) 2005-02-23 2010-11-27 Дженентек, Инк. Extension of time to progression of disease or lifetime of oncologic patients with application of her dimerisation inhibitors
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201708537A (en) 2006-09-13 2017-03-01 艾伯維有限公司 Cell culture improvements
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
CA2703279C (en) 2007-10-30 2014-04-22 Genentech, Inc. Antibody purification by cation exchange chromatography
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
TW201438738A (en) 2008-09-16 2014-10-16 Genentech Inc Methods for treating progressive multiple sclerosis
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN104974251A (en) * 2008-10-20 2015-10-14 Abbvie公司 Viral inactivation during purification of antibodies
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
US20120178910A1 (en) * 2009-09-23 2012-07-12 Medarex, Inc. Cation exchange chromatography (methods)
AR080794A1 (en) * 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
PE20130192A1 (en) * 2010-03-30 2013-02-27 Centocor Ortho Biotech Inc IL-25 HUMANIZED ANTIBODIES
CA2798136C (en) 2010-05-14 2019-06-04 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
SG185737A1 (en) * 2010-05-25 2013-01-30 Genentech Inc Methods of purifying polypeptides
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
EP2655412B1 (en) 2010-12-21 2018-01-17 F. Hoffmann-La Roche AG Isoform enriched antibody preparation and method for obtaining it
CN103547589A (en) * 2011-03-29 2014-01-29 葛兰素史密斯克莱有限责任公司 Buffer system for protein purification
EP2714713B1 (en) * 2011-05-26 2018-05-09 Dr. Reddy's Laboratories Limited Purification of anti-cd20 antibodies
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
CN116271013A (en) 2011-10-14 2023-06-23 霍夫曼-拉罗奇有限公司 Use of the HER2 dimerization inhibitor pertuzumab and articles of manufacture comprising the HER2 dimerization inhibitor pertuzumab
RU2478646C1 (en) * 2011-11-28 2013-04-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) Method for producing high-affinity polyclonal antibodies
MY172426A (en) 2011-12-22 2019-11-25 Genentech Inc Ion exchange membrane chromatography
MA37794B1 (en) 2012-07-13 2017-07-31 Roche Glycart Ag Anti-vegf / anti-ang-2 bispecific antibodies and their use in the treatment of ocular vascular pathologies
JP6253584B2 (en) * 2012-08-27 2017-12-27 旭化成メディカル株式会社 Antibody purification method by temperature-responsive chromatography
CN103217499B (en) * 2013-01-15 2015-12-02 珠海市丽珠单抗生物技术有限公司 A kind ofly measure the glycosylation of immunoglobulin charge isomer and the method for end modified situation
RU2768003C2 (en) 2013-03-08 2022-03-22 Джензим Корпорейшн Integrated continuous production of therapeutic protein-based medicinal agents
UY35517A (en) * 2013-04-04 2014-10-31 Mabxience S A A PROCEDURE TO INCREASE THE FORMATION OF PYROGLUTAMIC ACID OF A PROTEIN
EP3800204A1 (en) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
KR101700580B1 (en) * 2013-10-30 2017-02-13 (주)셀트리온 Method for separating antibody isoform by using cation exchange chromatography
CN104628846B (en) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 Method for purifying recombinant protein
SG10201710475WA (en) * 2013-11-25 2018-01-30 Seattle Genetics Inc Preparing antibodies from cho cell cultures for conjugation
TWI709569B (en) 2014-01-17 2020-11-11 美商健臻公司 Sterile chromatography resin and use thereof in manufacturing processes
TWI671312B (en) 2014-01-17 2019-09-11 美商健臻公司 Sterile chromatography and manufacturing processes
JP6609561B2 (en) * 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド Use of cation exchange chromatography in flow-through mode to enrich post-translational modifications
WO2015135884A1 (en) 2014-03-10 2015-09-17 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
CN105017418B (en) * 2014-03-27 2021-02-23 上海药明康德新药开发有限公司 Monoclonal antibody purification process
EP3581586A1 (en) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
KR102403547B1 (en) 2014-07-16 2022-05-30 오레곤 헬스 앤드 사이언스 유니버시티 Human cytomegalovirus comprising exogenous antigens
CN105315369B (en) * 2014-07-25 2020-03-13 山东博安生物技术有限公司 Purification of proteins by cation exchange chromatography
EA035635B1 (en) * 2015-03-13 2020-07-17 Бристол-Маерс Сквибб Компани Use of alkaline washes during chromatography to remove impurities
CN107614015A (en) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 Treat HER2 positives Locally Advanced or the previously method of untreated metastatic breast cancer
KR101657690B1 (en) * 2015-06-05 2016-09-19 주식회사 녹십자홀딩스 Methods for Preparing Hepatitis B immune globulin derived from plasma
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN108474003A (en) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 Include the CMV carriers of Microrna recognition component
GB201600512D0 (en) 2016-01-12 2016-02-24 Univ York Recombinant protein production
WO2017180936A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN109310756B (en) * 2016-05-13 2022-06-28 奥美药业有限公司 Novel angiopoietin 2, VEGF bispecific antagonists
CA3027143A1 (en) * 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
CN106222222B (en) * 2016-08-08 2019-10-29 湖北医药学院 A kind of preparation method of recombinant human leukemia inhibitory
WO2018045587A1 (en) * 2016-09-12 2018-03-15 广东东阳光药业有限公司 Purification method for anti-vegf type monoclonal antibody
CN106380519B (en) * 2016-10-17 2019-11-01 深圳万乐药业有限公司 A kind of purification process of monoclonal antibody
MX2019004518A (en) 2016-10-18 2019-06-17 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules.
EP3532498A1 (en) * 2016-10-31 2019-09-04 Hexal AG Antibody preparation
TW201827077A (en) 2016-12-28 2018-08-01 美商建南德克公司 Treatment of advanced her2 expressing cancer
LT3570884T (en) 2017-01-17 2020-12-10 Genentech, Inc. Subcutaneous her2 antibody formulations
AU2018227788B2 (en) 2017-03-02 2021-04-22 F. Hoffmann-La Roche Ag Adjuvant treatment of HER2-positive breast cancer
BE1025090B1 (en) * 2017-03-30 2018-10-29 Univercells Sa PROCESS AND KIT FOR PROTEIN PURIFICATION
TWI679209B (en) * 2017-04-14 2019-12-11 南韓商Ｃｊ醫藥健康股份有限公司 Method for purifying analogous antibody using cation-exchange chromatography
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
EP3642218A4 (en) 2017-06-21 2021-04-07 Cephalon, Inc. Cation exchange chromatography wash buffer
JP2020534332A (en) * 2017-09-22 2020-11-26 イミュノジェン， インコーポレイテッド Separation of triple light chain antibody using cation exchange chromatography
CN110272491B (en) * 2018-03-13 2023-01-24 江苏恒瑞医药股份有限公司 Purification process of anti-PD-1 antibody
CN112313248A (en) * 2018-03-29 2021-02-02 百时美施贵宝公司 Method for purifying monomeric monoclonal antibodies
CN112105927A (en) * 2018-05-08 2020-12-18 沃特世科技公司 Methods, compositions and kits useful for pH gradient cation exchange chromatography
SG11202101860UA (en) 2018-08-31 2021-03-30 Genzyme Corp Sterile chromatography resin and use thereof in manufacturing processes
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
CN109320611B (en) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 Purification method of human-mouse chimeric monoclonal antibody biological similar drug
CN112206327A (en) * 2019-07-12 2021-01-12 上海药明生物技术有限公司 Preparation of antibody coupling drug and high-throughput screening method thereof
EP4045917A1 (en) * 2019-10-14 2022-08-24 Pierce Biotechnology, Inc. Peptide purification formulations and methods
BR112022010069A2 (en) * 2019-11-25 2022-09-06 Akeso Biopharma Inc BIESPECIFIC ANTIBODY, ISOLATED NUCLEIC ACID MOLECULE, VECTOR, HOST CELL, CONJUGATE, KIT, USE OF BIESPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION
KR102153258B1 (en) * 2020-02-21 2020-09-07 프레스티지바이오로직스 주식회사 Optimized Method for Purification of Bevacizumab
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CN114591438B (en) * 2022-04-25 2023-12-05 达石药业(广东)有限公司 Method for purifying bispecific antibody by cation exchange chromatography
CN115850493B (en) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 Separation and purification method of bivalent nano antibody cablevi

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
GB2070818A (en) 1980-02-04 1981-09-09 Philips Electronic Associated Regulated power supply for an image intensifier
WO1984002129A1 (en) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
WO1986002068A1 (en) 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Mutual separation of proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5196323A (en) 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
CA1283072C (en) 1986-12-01 1991-04-16 Timothy Durance Process for the isolation and separation of lysozyme and avidin from eggwhite
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5451662A (en) 1987-10-23 1995-09-19 Schering Corporation Method of purifying protein
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IT1219874B (en) 1988-03-18 1990-05-24 Fidia Farmaceutici USE OF THE HUMAN NERVE GROWTH FACTOR AND ITS PHARMACEUTICAL COMPOSITIONS
US5115101A (en) 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
JP2749167B2 (en) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド Methods and therapeutic compositions for the treatment of myocardial infarction
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5112951A (en) 1989-07-28 1992-05-12 Hybritech Incorporated Separation of anti-metal chelate antibodies
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
EP0467466A1 (en) * 1990-07-16 1992-01-22 Eastman Kodak Company Method for the purification of immunoreactive labeled thyroxine conjugates
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
ES2296839T3 (en) 1991-08-14 2008-05-01 Genentech Inc. IMMUNOGLOBULIN VARIANTS FOR SPECIFIC FC-EPSILON RECEIVERS.
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
JPH05202098A (en) 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd Production of physiologically active substance from lactic material
ATE503496T1 (en) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
DE69315847T2 (en) 1992-08-21 1998-06-25 Genentech Inc METHOD FOR TREATING A FAULT BROUGHT BY LFA-1
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2091684T3 (en) 1992-11-13 1996-11-01 Idec Pharma Corp THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2176811C (en) 1993-12-10 2008-01-29 David Tai Wai Fei Methods for diagnosis of allergy and screening of anti-allergy therapeutics
AP660A (en) 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5702946A (en) 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
JPH11507535A (en) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP1297847A3 (en) 1996-01-23 2003-05-07 Genentech, Inc. Anti-CD18 antibodies in stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
JP4671372B2 (en) * 1996-11-15 2011-04-13 ジェネンテック， インコーポレイテッド Purification of neurotrophin
SI1897890T1 (en) 1996-11-27 2010-03-31 Genentech Inc Affinity purification of polypeptide on protein A matrix
JP3778945B2 (en) 1996-11-27 2006-05-24 ジェネンテック・インコーポレーテッド Humanized anti-CD11a antibody
KR100794454B1 (en) 1997-04-07 2008-01-16 제넨테크, 인크. Anti-VEGF Antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
JP2001511653A (en) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Apo-2 receptor
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
PT1308456E (en) * 1998-05-06 2007-12-03 Genentech Inc Antibody purification by ion exchange chromatography
IL139609A (en) 1998-06-01 2006-06-11 Genentech Inc Separation of polypeptide monomers
PL196770B1 (en) 1998-06-09 2008-01-31 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
HU226742B1 (en) 1999-06-25 2009-08-28 Genentech Inc Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
ATE400587T1 (en) 1999-10-29 2008-07-15 Genentech Inc ANTIBODIES DIRECTED AGAINST THE PROSTATE STEM CELL ANTIGEN (PSCA) AND THEIR USE
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
US6417355B1 (en) 2001-04-11 2002-07-09 The United States Of America As Represented By The Secretary Of The Navy Geminal-dinitro-1-5 diazocine derivatives
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6770027B2 (en) * 2001-10-05 2004-08-03 Scimed Life Systems, Inc. Robotic endoscope with wireless interface
WO2003033658A2 (en) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN101914158A (en) 2002-02-14 2010-12-15 免疫医疗公司 Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
CA2496060C (en) * 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
KR20100050587A (en) 2002-10-17 2010-05-13 젠맵 에이/에스 Human monoclonal antibodies against cd20
RU2005122033A (en) 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) DIRECTED ANTIMOLFOMY MEANS WITH EFFECTIVE AND AFFINAL FUNCTIONS ASSOCIATED BY A THREE-FUNCTIONAL REAGENT
JP4351674B2 (en) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド Immunoglobulin variants and their use and use
WO2004060920A1 (en) 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
AU2004252067B2 (en) 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
EP1651663B1 (en) 2003-08-08 2017-05-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR100524074B1 (en) 2003-10-01 2005-10-26 삼성전자주식회사 Electronic device having bezel structure
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US20060002930A1 (en) † 2004-04-16 2006-01-05 Genentech, Inc. Treatment of disorders
CN101022829A (en) * 2004-04-16 2007-08-22 健泰科生物技术公司 Treatment of polychondritis or mononeuritis multiplex by using an antibody against CD20
AU2005318999B2 (en) * 2004-12-22 2012-07-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
PT1869065T (en) * 2005-03-11 2020-06-18 Wyeth Llc A method of weak partitioning chromatography
EP2388274A1 (en) * 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
CA2645739A1 (en) * 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
CA2647029A1 (en) † 2006-04-05 2007-10-18 Abbott Biotechnology Ltd. Antibody purification
HUE045898T2 (en) * 2006-08-28 2020-01-28 Ares Trading Sa Process for the purification of fc-containing proteins
US8620738B2 (en) 2006-08-31 2013-12-31 Visa U.S.A. Inc Loyalty program incentive determination
JP5456658B2 (en) * 2007-03-30 2014-04-02 メディミューン，エルエルシー Antibody preparation
CA2703279C (en) * 2007-10-30 2014-04-22 Genentech, Inc. Antibody purification by cation exchange chromatography
JP5731726B1 (en) 2014-06-26 2015-06-10 楽天株式会社 Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
HK1182401A1 (en) 2013-11-29
HRP20150282T4 (en) 2018-08-10
US20090148435A1 (en) 2009-06-11
US9896478B2 (en) 2018-02-20
ES2533266T5 (en) 2018-04-18
CN101889025A (en) 2010-11-17
HK1143821A1 (en) 2011-01-14
IL239495B (en) 2019-09-26
PL2215117T3 (en) 2015-06-30
ZA201102169B (en) 2012-12-27
WO2009058812A1 (en) 2009-05-07
CN105315323A (en) 2016-02-10
DK2565206T3 (en) 2016-06-06
HK1221234A1 (en) 2017-05-26
HRP20150282T1 (en) 2015-06-19
IL205310A0 (en) 2010-12-30
NZ584839A (en) 2012-07-27
PT2215117E (en) 2015-04-01
DK2215117T4 (en) 2018-04-09
IL234902A0 (en) 2014-11-30
RS53850B2 (en) 2018-07-31
IL239495A0 (en) 2015-08-31
ZA201002850B (en) 2011-07-27
AR069097A1 (en) 2009-12-30
EP2215117B2 (en) 2018-01-10
TWI554517B (en) 2016-10-21
ES2666170T3 (en) 2018-05-03
EP2565206A3 (en) 2013-11-06
MX2010004740A (en) 2010-05-27
CN103554215B (en) 2016-06-15
US20180118781A1 (en) 2018-05-03
JP5885864B2 (en) 2016-03-16
HRP20180943T1 (en) 2018-08-10
JP2015145371A (en) 2015-08-13
SG175597A1 (en) 2011-11-28
JP2017019790A (en) 2017-01-26
CN101889025B (en) 2013-11-13
DK2215117T3 (en) 2015-03-02
KR20100086015A (en) 2010-07-29
AU2008318865A1 (en) 2009-05-07
HUE027668T2 (en) 2016-11-28
SI2215117T2 (en) 2018-04-30
RS53850B1 (en) 2015-08-31
CN103554215A (en) 2014-02-05
BRPI0817182A2 (en) 2015-03-17
HUE024877T2 (en) 2016-02-29
HK1206753A1 (en) 2016-01-15
IL234901A0 (en) 2014-11-30
SI2840090T1 (en) 2018-05-31
EP2215117B1 (en) 2014-12-31
PL2840090T3 (en) 2018-07-31
SI2565206T1 (en) 2016-07-29
JP2015155406A (en) 2015-08-27
SI2215117T1 (en) 2015-03-31
RU2498991C2 (en) 2013-11-20
EP2565206A2 (en) 2013-03-06
CY1116129T1 (en) 2017-02-08
ES2572958T3 (en) 2016-06-03
HUE037409T2 (en) 2018-08-28
EP2565206B1 (en) 2016-03-30
PE20091434A1 (en) 2009-10-17
US20150056196A1 (en) 2015-02-26
ES2533266T3 (en) 2015-04-08
RU2010121816A (en) 2011-12-10
EP3441402A1 (en) 2019-02-13
PL2215117T5 (en) 2018-06-29
DK2840090T3 (en) 2018-04-23
PH12013501128A1 (en) 2015-12-02
ME02101B (en) 2015-10-20
CA2703279A1 (en) 2009-05-07
TWI448330B (en) 2014-08-11
EP2840090A1 (en) 2015-02-25
TW201512216A (en) 2015-04-01
KR101241486B1 (en) 2013-03-15
JP2011502161A (en) 2011-01-20
EP2840090B1 (en) 2018-02-21
EP2215117A1 (en) 2010-08-11
AR111171A2 (en) 2019-06-12
PL2565206T3 (en) 2017-08-31
JP2013173747A (en) 2013-09-05
AU2008318865B2 (en) 2012-06-28
JP5237382B2 (en) 2013-07-17
KR20140015166A (en) 2014-02-06
CL2008003218A1 (en) 2009-03-06
TW200927289A (en) 2009-07-01
CA2703279C (en) 2014-04-22
KR20150008503A (en) 2015-01-22
CO6280422A2 (en) 2011-05-20

Similar Documents

Publication Publication Date Title
HK1221234A1 (en) Antibody purification by cation exchange chromatography
IL194236A0 (en) Antibody purification
IL201388A0 (en) Immunoglobulin purification
HK1138790A1 (en) Anti-sclerostin antibodies
PT2195026E (en) Anti-sclerostin antibodies
EP2265129A4 (en) Chromatography purification of antibodies
EP2519536A4 (en) Protein purification by ion exchange
PL1985871T3 (en) System for attaching two parts to one another
IL225720A0 (en) Single unit ion exchange chromatography antibody purification
EP2125890A4 (en) Antibodies to phosphorylated-irak4
IL212646A0 (en) Immunoglobulin purification
EP2212431A4 (en) Antibodies to irem-1
HK1198653A1 (en) Protein purification by anion exchange chromatography
HK1198588A1 (en) Protein purification by anion exchange chromatography
ZA201100565B (en) Antibody purification
IL211067A0 (en) Affinity purification by cohesin-dockerin interaction
GB0517651D0 (en) Alterations to pipe movement apparatus
GB0724148D0 (en) Improvements relating to column chromatography